BioNTech SE
BNTXBioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Drugs in Pipeline
38
Phase 3 Programs
18
Upcoming Catalysts
2
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
2 upcoming, 4 past
How BNTX's past catalysts played out
Influenza and COVID-19 Combination A
Influenza
BNT162b2 (2025/2026 formulation)
COVID-19
BNT162b2
SARS-CoV-2 Infection
Biological/Vaccine: BNT162b2 10mcg
SARS-CoV-2 Infection, COVID-19
BNT162b2 OMI
SARS-CoV-2 Infection
BNT162b2.B.1.351
SARS-CoV-2 Infection
BNT162b1
SARS-CoV-2 Infection
BNT162b2 (Omi LP.8.1)
COVID-19
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
SARS-CoV-2 Virus
BNT162b2 (Omi XBB.1.5)
SARS-CoV-2 Infection
BNT162b5 Bivalent (WT/OMI BA.2)
SARS-CoV-2 Infection
Seasonal Inactivated Influenza Vaccine
SARS-CoV-2 Infection
BNT113
Unresectable Head and Neck Squamous Cell Carcinoma
Investigational Influenza Vaccine
Influenza,Human
BNT162b2 Vaccine
COVID-19
BNT324
Advanced Lung Cancer
Prednisone/prednisolone
Metastatic Castration-resistant Prostate Cancer
Pumitamig
Extensive-stage Small-cell Lung Cancer
BNT164a1
Tuberculosis
BNT327 Dose Level 1 (DL2)
Locally Advanced Breast Cancer
BNT3214
Advanced Solid Tumor Cancer
BNT329
Advanced Solid Cancers
BNT326
Advanced Solid Tumor
BNT162b3
Covid-19
BNT111
Melanoma Stage III
BNT314
Metastatic Colorectal Cancer
bivalent BNT162b2 (original/Omi BA.4/BA.5)
Influenza, Human
BNT162b2s01
COVID-19
BNT327
Non-small Cell Lung Cancer
BNT142
Solid Tumor
BNT3212
Advanced Solid Tumor
RO7198457 intravenous (IV)
Colorectal Cancer Stage II
BNT166a
Monkeypox
BNT323
Locally Advanced Breast Cancer
Investigational COVID-19 Vaccine
Influenza
BNT165e
Malaria
BNT162a1
Infections, Respiratory
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
SARS-CoV-2 Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Influenza and COVID-19 Combination A | Phase 3 | Influenza | - | - |
BNT162b2 (2025/2026 formulation) | Phase 3 | COVID-19 | - | - |
BNT162b2 | Phase 3 | SARS-CoV-2 Infection | - | - |
Biological/Vaccine: BNT162b2 10mcg | Phase 3 | SARS-CoV-2 Infection, COVID-19 | - | - |
BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2.B.1.351 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b1 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 (Omi LP.8.1) | Phase 3 | COVID-19 | - | - |
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
BNT162b2 (Omi XBB.1.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | SARS-CoV-2 Infection | - | - |
Seasonal Inactivated Influenza Vaccine | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT113 | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma | - | - |
Investigational Influenza Vaccine | Phase 3 | Influenza,Human | - | - |
BNT162b2 Vaccine | Phase 3 | COVID-19 | - | - |
BNT324 | Phase 3 | Advanced Lung Cancer | - | - |
Prednisone/prednisolone | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
BNT164a1 | Phase 2 | Tuberculosis | - | - |
BNT327 Dose Level 1 (DL2) | Phase 2 | Locally Advanced Breast Cancer | - | - |
BNT3214 | Phase 2 | Advanced Solid Tumor Cancer | - | - |
BNT329 | Phase 2 | Advanced Solid Cancers | - | - |
BNT326 | Phase 2 | Advanced Solid Tumor | - | - |
BNT162b3 | Phase 2 | Covid-19 | - | - |
BNT111 | Phase 2 | Melanoma Stage III | - | - |
BNT314 | Phase 2 | Metastatic Colorectal Cancer | - | - |
bivalent BNT162b2 (original/Omi BA.4/BA.5) | Phase 2 | Influenza, Human | - | - |
BNT162b2s01 | Phase 2 | COVID-19 | - | - |
BNT327 | Phase 2 | Non-small Cell Lung Cancer | - | - |
BNT142 | Phase 2 | Solid Tumor | - | - |
BNT3212 | Phase 2 | Advanced Solid Tumor | - | - |
RO7198457 intravenous (IV) | Phase 2 | Colorectal Cancer Stage II | - | - |
BNT166a | Phase 2 | Monkeypox | - | - |
BNT323 | Phase 2 | Locally Advanced Breast Cancer | - | - |
Investigational COVID-19 Vaccine | Phase 2 | Influenza | - | - |
BNT165e | Phase 2 | Malaria | - | - |
BNT162a1 | Phase 2 | Infections, Respiratory | - | - |
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | Phase 2 | SARS-CoV-2 Infection | - | - |
SARS-CoV-2 Infection
8 drugs in this indication
COVID-19
4 drugs in this indication
Influenza
2 drugs in this indication
Influenza,Human
2 drugs in this indication
Locally Advanced Breast Cancer
2 drugs in this indication
Advanced Solid Tumor
2 drugs in this indication
oncology/cancer
1 drug in this indication
Unresectable Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Advanced Lung Cancer
1 drug in this indication
Colorectal Cancer Stage II
1 drug in this indication
Monkeypox
1 drug in this indication
SARS-CoV-2 Virus
1 drug in this indication
Non-small Cell Lung Cancer
1 drug in this indication
Tuberculosis
1 drug in this indication
Malaria
1 drug in this indication
SARS-CoV-2 Infection, COVID-19
1 drug in this indication
Infections, Respiratory
1 drug in this indication
Extensive-stage Small-cell Lung Cancer
1 drug in this indication
Solid Tumor
1 drug in this indication
Advanced Solid Cancers
1 drug in this indication
respiratory syncytial virus
1 drug in this indication
Metastatic Colorectal Cancer
1 drug in this indication
Melanoma Stage III
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioNTech SE's drug pipeline?→
CatalystAlert tracks 38 drug candidates in BioNTech SE's (BNTX) pipeline across Phase 3, Phase 2. Its lead program is Influenza and COVID-19 Combination A (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioNTech SE's next FDA catalyst?→
BioNTech SE's (BNTX) next tracked catalyst is a Phase 3 expected July 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BNTX biotech catalysts?→
Add BNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioNTech SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.